Prescrire international
-
Prescrire international · Apr 2002
Comparative StudyCapecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
(1) The standard chemotherapy for metastatic colorectal cancer is intravenous fluorouracil combined with calcium folinate. This treatment improves the median survival time by approximately 4-6 months compared with optimal palliative care. (2) Two metabolic precursors of fluorouracil are now available in the European Union for first-line oral treatment of metastatic colorectal cancer, namely capecitabine and tegafur + uracil. According to the licensing terms, only the tegafur-uracil combination must be given with calcium folinate. (3) The evaluation files on each of these two cytotoxic agents contain data from two comparative unblinded trials versus intravenous fluorouracil + calcium folinate (Mayo Clinic protocol). ⋯ Longer postmarketing follow-up is available for the tegafur + uracil combination, which has been used in Japan for many years. (5) Patients receiving capecitabine or tegafur + uracil + calcium folinate have to take large numbers of tablets or capsules. (6) In practice, the standard treatment for metastatic colorectal cancer remains the fluorouracil + calcium folinate combination. The tegafur + uracil + calcium folinate combination is only useful for patients who prefer oral administration. Capecitabine has no documented advantage over this latter combination.